| Appendiceal mucinous neoplasms: diagnosis and management WL Shaib, R Assi, A Shamseddine, OB Alese, C Staley III, B Memis, ... The oncologist 22 (9), 1107-1116, 2017 | 196 | 2017 |
| Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia R Assi, H Kantarjian, NJ Short, N Daver, K Takahashi, G Garcia-Manero, ... Clinical Lymphoma Myeloma and Leukemia 17 (12), 897-901, 2017 | 150 | 2017 |
| JAK2 inhibitors for myeloproliferative neoplasms: what is next? P Bose, S Verstovsek Blood, The Journal of the American Society of Hematology 130 (2), 115-125, 2017 | 130 | 2017 |
| Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study F Ravandi, R Assi, N Daver, CB Benton, T Kadia, PA Thompson, ... The Lancet Haematology 6 (9), e480-e488, 2019 | 119 | 2019 |
| Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors R Assi, H Kantarjian, F Ravandi, N Daver Current opinion in hematology 25 (2), 136-145, 2018 | 90 | 2018 |
| Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk … R Assi, HM Kantarjian, TM Kadia, N Pemmaraju, E Jabbour, N Jain, ... Cancer 124 (13), 2758-2765, 2018 | 85 | 2018 |
| Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid … K Sasaki, R Kanagal‐Shamanna, G Montalban‐Bravo, R Assi, E Jabbour, ... Cancer 126 (4), 765-774, 2020 | 82 | 2020 |
| Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia NJ Short, KP Patel, M Albitar, M Franquiz, R Luthra, ... Blood advances 4 (8), 1670-1677, 2020 | 69 | 2020 |
| A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms R Assi, HM Kantarjian, G Garcia‐Manero, JE Cortes, N Pemmaraju, ... American journal of hematology 93 (2), 277-285, 2018 | 61 | 2018 |
| Metastatic colorectal cancer presenting with bone marrow metastasis: a case series and review of literature R Assi, D Mukherji, A Haydar, M Saroufim, S Temraz, A Shamseddine Journal of gastrointestinal oncology 7 (2), 284, 2016 | 52 | 2016 |
| The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia M Alfayez, GC Issa, KP Patel, F Wang, X Wang, NJ Short, JE Cortes, ... Leukemia 35 (3), 691-700, 2021 | 51 | 2021 |
| Programmed death-ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: a reliable treatment selection biomarker? D Mukherji, MN Jabbour, M Saroufim, S Temraz, R Nasr, M Charafeddine, ... Clinical Genitourinary Cancer 14 (2), 183-187, 2016 | 50 | 2016 |
| Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia R Assi, G Garcia‐Manero, F Ravandi, G Borthakur, NG Daver, E Jabbour, ... Cancer 124 (21), 4192-4201, 2018 | 40 | 2018 |
| Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology DA Pollyea, JK Altman, R Assi, D Bixby, AT Fathi, JM Foran, I Gojo, ... Journal of the National Comprehensive Cancer Network 21 (5), 503-513, 2023 | 29 | 2023 |
| Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia CB Benton, PC Boddu, CD DiNardo, P Bose, F Wang, R Assi, ... Cancer 125 (11), 1855-1866, 2019 | 28 | 2019 |
| Results of a phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high-risk … R Assi, HM Kantarjian, NG Daver, G Garcia-Manero, CB Benton, ... Blood 132, 905, 2018 | 28 | 2018 |
| FLT3 inhibitors in acute myeloid leukemia: choosing the best when the optimal does not exist R Assi, F Ravandi American journal of hematology 93 (4), 553-563, 2018 | 25 | 2018 |
| Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML M Yilmaz, M Alfayez, CD DiNardo, G Borthakur, TM Kadia, MY Konopleva, ... Journal of hematology & oncology 13, 1-12, 2020 | 20 | 2020 |
| Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome K Naqvi, K Sasaki, G Montalban‐Bravo, A Alfonso Pierola, M Yilmaz, ... Cancer 125 (13), 2233-2241, 2019 | 20 | 2019 |
| Hemophagocytic lymphohistiocytosis in adults: An under recognized entity AR Shah, T Muzzafar, R Assi, D Schellingerhout, Z Estrov, G Tamamyan, ... BBA clinical 7, 36-40, 2017 | 20 | 2017 |
Guillermo Garcia-ManeroMD Anderson Cancer CenterVerified email at mdanderson.org
